Clinical trial of ReoGo for the rehabilitation of post-stroke hemiplegia - exploratory study

Clinical trial of ReoGo for the rehabilitation of post-stroke hemiplegia - exploratory study - Clinical trial of ReoGo for the rehabilitation of post-stroke hemiplegia - exploratory study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001619

Enrollment

Registered

2009-02-01

Start date

2009-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

6 week intervention (7 days a week). After a regular rehabilitation session for upper extremity by PT or OT (2 credit, 40 minutes), receive a training session using ReoGo (40 minutes). 6 week interven

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patient with post-stroke hemiplegia 2.Those who are expected to be administered in rehabilitation ward throughout the study phase 3.4-8 weeks post-stroke 4.Brunnstrom Stage III or IV at the time of informed consent

Exclusion criteria

Exclusion criteria: 1.Stoke at brainstem 2.Vision problem 3.Hemorrhagic infarct patient, or subarachnoid hemorrhage patient 4.Problem with sever sensory aphasia 5.Unable to sit still during therapy 6.have significant pain in upper extremity by passive movement 7.Incapable to consent voluntary due to cognitive problem 8.Participated in other clinical study using robotic rehabilitation for upper extremity 9.Received Constrained Induced Movement Therapy for upper extremity 10.Received FES therapy for upper extremity 11.Has heart or respiration problem which could interfere with rehabilitation 12.Has other neuro-muscular disease 13.Weight over 110kg 14.Others when Clinical Trial Coordinator (physician) considered to be unsuitable in this study

Design outcomes

Primary

Measure	Time frame
(Outcome Measurements) Baseline, 3 week post, and Post-intervnetion (6 weeks) <Impairment assessment of U/E> 1.Brunnstrom Stage (BS) : U/E 2.Fugl-Meyer (FM) : U/E 3.STEF : All item 4.Motricity Index (MI) : Shoulder and Elbow Flexors 5.Modified Ashworth Scale (MAS) : Elbow flexor and extensor, Spinator, Pronator 6.Wolf Motor Function Test (WMFT) : all 15 items 7.Range of Motion (ROM) : Shoulder, Elbow, Arm, and Wrist <Functional assessment of U/E> 1.Functional Independence Measure (FIM) : all 18 items 2.Motor Activity Log (MAL) : 14 items <Other> 1.Visual Analog Scale (VAS) : Most painful part of U/E (Safety Evaluation) Adverse Event and Intervention Status Report will be collected everyday. Physiological Evaluation will be collected on the same day of outcome measurements. 1.Adverse Event 2.Intervention Status Report 3.Physiological Evaluation	—

Measure

Time frame

(Outcome Measurements) Baseline, 3 week post, and Post-intervnetion (6 weeks) <Impairment assessment of U/E> 1.Brunnstrom Stage (BS) : U/E 2.Fugl-Meyer (FM) : U/E 3.STEF : All item 4.Motricity Index (MI) : Shoulder and Elbow Flexors 5.Modified Ashworth Scale (MAS) : Elbow flexor and extensor, Spinator, Pronator 6.Wolf Motor Function Test (WMFT) : all 15 items 7.Range of Motion (ROM) : Shoulder, Elbow, Arm, and Wrist <Functional assessment of U/E> 1.Functional Independence Measure (FIM) : all 18 items 2.Motor Activity Log (MAL) : 14 items <Other> 1.Visual Analog Scale (VAS) : Most painful part of U/E (Safety Evaluation) Adverse Event and Intervention Status Report will be collected everyday. Physiological Evaluation will be collected on the same day of outcome measurements. 1.Adverse Event 2.Intervention Status Report 3.Physiological Evaluation

—

Countries

Japan

Contacts

Public ContactHiroshi Kanatani

TEIJIN PHARMA LIMITED Home Healthcare Research & Development Department

h.kanatani@teijin.co.jp03-3506-4889

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026